Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Appeals court sides with women who took Prempro

By R&D Editors | July 27, 2012

A federal appeals court on Thursday sided with two women who developed breast cancer after taking the hormone therapy drug Prempro and sent their cases back for more proceedings.

The 8th U.S. Circuit Court of Appeals said a federal magistrate judge abused his discretion when he blocked expert testimony from a doctor on behalf of Pamela Kuhn and Shirley Davidson.

Kuhn took Prempro, which is used to treat symptoms of menopause, for a little more than three years, while Davidson took it for a year and nine months, the court said. Both women developed breast cancer and sued the drug’s manufacturer, Wyeth. The company moved to block any expert testimony about the use of Prempro increasing breast cancer risk when taken for three years or less.

The magistrate judge sided with Wyeth and precluded testimony from a doctor who said that short-term use of Prempro increases the risk of breast cancer.

“We conclude that the magistrate judge abused his discretion in precluding Dr. (Donald) Austin’s expert testimony, and thus we reverse and remand for further proceedings,” Judge Roger Wollman wrote for two members of the three-judge panel.

Judge James Loken dissented.

Wyeth is now a subsidiary of Pfizer Inc., which spokesman Chris Loder said is considering its legal options.

The district court’s ruling “was well supported by the evidence, which included findings from the Women’s Health Initiative (WHI) showing no evidence that Prempro use for three years or less increases the risk of breast cancer,” Loder said in a statement.

Erik Walker, an Austin, Texas-based attorney for Davidson and Kuhn, applauded the appeals court’s decision.

“We did think the court had gone into the realm of the jury” instead of acting as a gatekeeper, Walker said.

A hearing has not been set yet for either Kuhn or Davidson.

___

Follow Jeannie Nuss at http://twitter.com/jeannienuss

Related Articles Read More >

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
Waters touts six-fold robustness with new Xevo TQ Absolute XR
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE